Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
August 17, 2026
Earning the Right to Grow
Kymera Founders Nello Mainolfi & Bruce Booth
April 15, 2026
A Conversation with Kymera’s Chief Business Officer, Noah Goodman
Noah Goodman, MBA, Chief Business Officer
May 7, 2026
Ten Years of Kymera: Daring to Deliver on a New Class of Medicines
Nello Mainolfi, PhD, Founder, President and CEO
Showing 51 news results
April 24, 2026
Healio: FDA Grants Fast Track Designation to KT-621 for Moderate to Severe Eosinophilic Asthma
April 1, 2026
Dermatology Times: 85% of Biologic-Eligible AD Patients Left Behind — Can KT-621 Reach Them?
December 8, 2025
STAT News: Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
December 8, 2025
Endpoints News: Kymera’s Dupixent-in-a-pill impresses in closely-watched early eczema readout
December 8, 2025
Barron’s: Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug.
September 19, 2025
Dermatology Times: KT-621 Shows Strong Phase 1 Results as First-in-Class Oral STAT6 Degrader
Featured Presentations & Publications
September 17, 2025
KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects
European Academy of Dermatology & Venereology (EADV) 2025 – Late Breaking Presentation
October 27, 2025
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
American College of Rheumatology (ACR) 2025